ASX/AIM Announcement
19 September 2025
Wellnex Life Limited (ASX/AIM:WNX)
Expanded Financing Facility
Wellnex Life Limited (ASX/AIM: WNX) (Wellnex Life or Company) announces that, further to the Company's announcement on 31 July 2025, the Group has entered into an additional loan facility via Reach Wholesale ("Reach") for up to A$2.5 million (the "Additional Facility"). The Additional Facility, which is secured over the assets of the Group's key subsidiaries, is for a 24-month term at an interest rate of 14% for the term of the Additional Facility. The coupon and key terms are the same terms as the loan facility via Reach announced on 31 July 2025.
The Additional Facility will serve to ensure that the Company has the maximum flexibility available to support continued growth in the business. A$1.31 million is being drawn down immediately under the Additional Facility, which will be applied towards settlement of long-term obligations and towards general working capital. A further drawdown of A$0.365 million is expected shortly. The balance of A$0.825 million requires the prior approval of Reach in their absolute discretion.
To stay up to date on company news and announcements, please register your details on the Wellnex Life Limited investor portal: https://wellnexlife.investorportal.com.au/register/
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
For further information, please contact:
Wellnex Life Limited (ASX:WNX) Reach Markets
Zack Bozinovski T: 1300 805 795
Chief Executive Officer & Managing Director E: [email protected]
P: +61 3 8399 9419
UK Investors
Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494
Orana Corporate LLP (Joint Broker) [email protected]
Sebastian Wykeham
S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre
About Wellnex Life
Wellnex Life Limited (ASX/AIM:WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing on ASX in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the Company's registered products a distribution channel with a steadily increasing global geographic footprint.
In December 2023, Wellnex Life acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.
The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.
To learn more, please visit: www.Wellnex Lifelife.com.au/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.